Video

Listen as Dr. John Lewis speaks on the CBC’s podcast The Dose by Dr. Brian Goldman: Prostate cancer is the most common cancer among Canadian men, with an estimated one in eight men expected to be diagnosed during their lifetime. John Lewis, a prostate cancer researcher and University of Alberta oncology professor, says better screening tools will help detect the disease more effectively in men.

Sean Secord had the opportunity to speak at PROSTAID’s monthly meeting in Calgary, where he discussed the importance of prostate cancer screening and the impact ClarityDX Prostate can have on patients’ lives. The group was very engaged and raised thoughtful questions around screening frequency, accuracy, and what the future of prostate health management could look like with ClarityDX Prostate.

Nanostics was excited to be the first to be featured on a new podcast by AIMSS, called ByteMed! Watch us delve into the transformative world of diagnostic technology. Discover how the innovative platform, ClarityDX®, harnesses advanced machine learning algorithms to create noninvasive disease risk scores, particularly in the realm of cancer detection.

Sean Secord and Robert Paproski from Nanostics Inc. had the chance to discuss the critical importance of early prostate cancer detection and how ClarityDX leverages machine learning to improve patient outcomes. They also shared some interesting insights—be sure to listen to the full conversation!